3-Arylidene-N-hydroxyoxindoles: A New Class of Compounds Endowed with Antitumor Activity

Area of Science:

• Medicinal Chemistry
• Cancer Biology
• Pharmacology

Background:

• The N-hydroxyoxindole scaffold is a promising structural motif for drug development.
• The role of the p53 tumor suppressor gene in mediating cellular response to cytotoxic agents is well-established.
• Ovarian carcinoma cell lines with differing p53 functional status provide a model to study drug sensitivity.

Purpose of the Study:

• To synthesize and evaluate a series of N-hydroxyoxindole derivatives for antitumor activity.
• To investigate the influence of p53 status on the antiproliferative and pro-apoptotic effects of these compounds.
• To assess the therapeutic potential of the lead compound in a preclinical animal model.

Main Methods:

• Synthesis of novel N-hydroxyoxindole compounds.
• In vitro antiproliferative assays using wild-type p53 (IGROV-1) and p53-deficient (IGROV-1/Pt1) ovarian cancer cell lines.
• Apoptosis assays to determine cell death mechanisms.
• In vivo efficacy study using an IGROV-1 xenograft ascites mouse model with intraperitoneal administration.

Main Results:

• The synthesized N-hydroxyoxindole compounds exhibited potent antiproliferative activity against the p53-proficient IGROV-1 cell line.
• Efficacy was significantly reduced in the p53-deficient IGROV-1/Pt1 subline, indicating p53-dependent cytotoxicity.
• Compounds induced differential susceptibility to apoptosis based on p53 status.
• The lead compound demonstrated therapeutic potential by significantly delaying ascites onset in the in vivo model after four weeks of daily treatment.

Conclusions:

• The p53 transcription factor is a critical determinant of N-hydroxyoxindole compound cytotoxicity in ovarian cancer cells.
• N-hydroxyoxindole derivatives represent a promising class of anticancer agents, with efficacy influenced by p53 status.
• Further development of these compounds may offer a therapeutic strategy for p53-proficient ovarian cancers.